Advanced Enzyme Technologies is seeking shareholder approval for a final dividend of ₹1.35 per share and significant related-party transactions with its subsidiary, JC Biotech. The company also proposed re-appointing its statutory auditor and a Whole-time Director.
Advanced Enzyme Technologies Ltd. AGM Agenda Highlights
Advanced Enzyme Technologies Ltd. is convening its 37th Annual General Meeting (AGM) on July 31, 2026, seeking shareholder approval for key corporate actions and transactions.
What just happened
The company proposed a final dividend of ₹1.35 per equity share for the financial year ending March 31, 2026. Shareholders will vote on material related party transactions with subsidiary JC Biotech Private Limited (JCB), with proposed purchase limits of ₹95 crore and sale limits of ₹5 crore. The re-appointment of statutory auditors M/s. MSKA & Associates LLP for a second five-year term and Mr. Mukund Madhusudan Kabra as Whole-time Director for five years from April 1, 2027, are also on the agenda.
Why this matters
These proposals provide clarity on dividend distribution and inter-company transactions. The substantial proposed transaction limits with JCB indicate its strategic importance within the group. The re-appointments signal stability in financial oversight and management.
The backstory
JC Biotech Private Limited, the subsidiary, reported a turnover of ₹72.8 crore and a profit after tax of ₹2.9 crore, with a net worth of ₹66.2 crore. Mr. Mukund Madhusudan Kabra's remuneration for FY 2025-26 was ₹2.865 crore. The company has been focusing on operational synergies and arm's length transactions.
What changes now
Shareholder approval at the AGM is required for the dividend payout and the related party transaction limits to be effective. The record date for the dividend entitlement is July 24, 2026. The auditor's reappointment and director's re-appointment will ensure continuity in governance and operations.
Risks to watch
Investors should monitor the actual utilization of the proposed transaction limits with JC Biotech to ensure they align with stated operational synergies and contribute positively to consolidated financials. Any deviations could raise governance concerns.
Peer comparison
While specific peer dividend policies and inter-subsidiary transaction sizes are not detailed in this filing, the proposed dividend yield and transaction scale should be assessed against industry norms and the company's own historical performance and strategic goals.
Context metrics (time-bound)
- Dividend: ₹1.35 per Equity Share (FY 2025-26)
- Record Date: July 24, 2026
- AGM Date: July 31, 2026
- JCB Proposed Purchase Limit: ₹95 crore (until 38th AGM)
- JCB Proposed Sale Limit: ₹5 crore (until 38th AGM)
- Auditor Re-appointment: 5 years (until 42nd AGM)
- Director Re-appointment: 5 years (from April 1, 2027)
- JCB Turnover: ₹72.8 crore (FY 2025-26)
- JCB PAT: ₹2.9 crore (FY 2025-26)
What to track next
Investors should closely watch the outcomes of the AGM, particularly the shareholder voting on the proposed transactions and dividend approval. Monitoring the actual transaction volumes with JC Biotech in the upcoming fiscal year will be crucial.